scholarly journals Introducing a novel chemotherapeutic drug for the treatment of oral ‎squamous cell carcinoma‎: Silver nanoparticles green-formulated by ‎ ‎Matricaria chamomilla

Author(s):  
Rui Yang ◽  
Mingguo Wang ◽  
Xiaoxia Ma ◽  
Qing Gao

IntroductionIn the present research, we formulated a modern chemotherapeutic drug by silver nanoparticles ‎‎(AgNPs) containing Matricaria chamomilla aqueous extract for the treatment of oral squamous ‎cell carcinoma.Material and methodsCharacterization of AgNPs was done by UV–Visible Spectroscopy (UV-Vis), Fourier ‎Transformed Infrared Spectroscopy (FT‐IR), Transmission Electron Microscopy (TEM), and ‎Field Emission Scanning Electron Microscopy (FE‐SEM). For investigating the antioxidant ‎properties of AgNO3, M. chamomilla, and AgNPs, the DPPH test was used in the presence of ‎butylated hydroxytoluene as the positive control. To survey the cytotoxicity and anti-oral ‎squamous cell carcinoma effects of AgNO3, M. chamomilla, and AgNPs, MTT assay was used ‎on the HSC-4, Ca9-22, and HSC-3 cell lines. ‎ResultsDPPH test revealed similar antioxidant potentials for M. chamomilla‎, AgNPs, and butylated ‎hydroxytoluene. Silver nanoparticles had very low cell viability and anti-oral squamous cell ‎carcinoma properties dose-dependently against HSC-4, Ca9-22, and HSC-3 cell lines without ‎any cytotoxicity on the normal cell line. The best result of anti-oral squamous cell carcinoma ‎properties of AgNPs against the above cell lines was seen in the case of the HSC-3 cell line. ‎ConclusionsAccording to the above findings, the silver nanoparticles containing M. chamomilla aqueous ‎extract can be administrated in humans for the treatment of several types of oral squamous cell ‎carcinoma. ‎

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Ping Zhou ◽  
Lei Xiao ◽  
Xiaonan Xu

Abstract Background As a tumor-accelerating transcriptional factor, E2F transcription factor 7 (E2F7) was up-regulated in many forms of cancers. Nevertheless, little has been reported about the impacts of E2F7 on oral squamous cell carcinoma (OSCC). Here, we aimed to probe whether E2F7 had influences on OSCC and its potential mechanism. Methods The expression of E2F7 in OSCC tissues was analyzed using the data acquired from TCGA and ONCOMINE databases. E2F7 prognostic value in OSCC patients was analyzed utilizing TCGA database. The expression of E2F7 in OSCC cell lines was detected by qRT-PCR. Gain-and loss-function of E2F7 assays in TCA-83 and CAL27 cells were performed respectively to inquire the function of E2F7. Western blotting was applied to test the alternations of EMT-related markers. Results In OSCC tissues, E2F7 was highly expressed. Besides, high expression of E2F7 predicted worse prognosis in OSCC patients. Moreover, E2F7 was over-expressed in TCA-83, HSC-4 and CAL27 (all OSCC cell lines) cells relative to that in HNOK (a normal cell line) cells. Gain-and loss-function assays displayed that deficiency of E2F7 suppresses CAL27 cell growth, migration, invasion and E2F7 high-expression resulted in inverse outcomes in TCA-83 cells. Finally, we found that silencing of E2F7 facilitated E-cadherin protein expression level and reduced N-cadherin, Vimentin and Snail protein levels in CAL27 cells, whilst E2F7 high-expression exhibited the opposite effects in TCA-83 cells. Conclusions These outcomes indicated that E2F7 performs a carcinogenic role in OSCC, which provides a theoretical basis for the therapeutic strategies of OSCC.


2020 ◽  
Vol 11 (4) ◽  
pp. 72
Author(s):  
Jordan Ringer ◽  
Bryan Morrison ◽  
Karl Kingsley

Introduction: Previous studies have demonstrated that glycosaminoglycan hyaluronic acid (HA) is capable of mediating oral tumor growth. Some clinical evidence has suggested reduced HA expression predicts poor cancer prognosis and that HA-chemotherapy conjugates may function synergistically to inhibit oral tumor growth. Other studies have found conflicting results that suggest enhanced CD44-HA-mediated growth and proliferation. Due to the lack of clarity regarding HA function, the primary goal of this study was to investigate the effects of HA using well-characterized oral cancer cell lines. Methods: Using several commercially available oral squamous cell carcinoma lines (and a normal non-cancerous control), 96-well growth and viability assays were conducted using HA (alone and in combination with chemotherapeutic agents paclitaxel and PD98059). Results: Different results were observed in each of the cell lines evaluated. HA induced small, non-significant changes in cellular viability among each of the cell lines within a narrow range (1–8%), p = 0.207. However, HA induced differing effects on growth, with minimal, non-significant changes among some cell lines, such as SCC4 (+1.7%), CCL-30 (−2.8%), and SCC15 (−2.5%), p = 0.211 and more robust inhibition among other cell lines, SCC9 (−24.4%), SCC25 (−36.6%), and CAL27 (−47.8%), p = 0.0001. Differing effects were also observed with growth and viability under concomitant administration of HA with PD98059 or paclitaxel. Further analysis of these data revealed strong inverse (Pearson’s) correlations between initial baseline growth rate and responsiveness to HA administration, ranging from R = −0.27 to R = −0.883. Conclusion: The results of this study revealed differing responses to HA, which may be inversely correlated with intrinsic characteristics, such as the baseline growth rate. This may suggest that the more rapidly growing cell lines are more responsive to combination therapy with hyaluronic acid; an important finding that may provide insights into the mechanisms responsible for these observations.


Oncotarget ◽  
2016 ◽  
Vol 7 (19) ◽  
pp. 27802-27818 ◽  
Author(s):  
Muhammad Zaki Hidayatullah Fadlullah ◽  
Ivy Kim-Ni Chiang ◽  
Kalen R. Dionne ◽  
Pei San Yee ◽  
Chai Phei Gan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document